entertainment -WSS

entertainment

author：knowledge 2025-09-30 19:27:11 - browse：8136

The profit margin at Optum Health is at the lowest in a decade. Courtesy United

Just weeks after the division of UnitedHealth Group that provides care to patients posted its lowest profit margin in a decade, the company has shuffled around several top executives.

Amar Desai is now CEO of Optum Health, according to a July LinkedIn post. Optum Health encompasses UnitedHealth’s physician practices, surgery centers, urgent care clinics, and other providers. Desai took over for Wyatt Decker, who moved into the role of chief physician overseeing “value-based care” across all of UnitedHealth.

Heather Cianfrocco also became the president of Optum, a separate LinkedIn post from last week shows. That makes her one of the most powerful people overseeing all aspects of Optum. She most recently was CEO of Optum Rx, UnitedHealth’s pharmacy benefit manager, one of the largest in the country. Patrick Conway, a former top Medicare official in the Obama administration and former head of Blue Cross Blue Shield of North Carolina, is now the CEO of Optum Rx.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Why a market frenzy over new weight loss drugs defies logic

WSS

Roche acquires Telavant from Roivant, adding experimental IBD treatment

How AI can help patients find reliable information about doctors

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Why are Kaiser Permanente staff considering a strike?

Biotech stock slump in 2023: awaiting the turnaround

Why a market frenzy over new weight loss drugs defies logic

explore

entertainment

entertainment

Peter Hotez and the public health issue of online harassment

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medical records are filled with copy

CDC's new outbreak response network to include Northeastern

Heart attack and stroke risk calculators need revising

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Roche acquires Telavant from Roivant, adding experimental IBD treatment

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

hotspot

How AI helped researchers track recovery from depression

Thermo Fisher plant for manufacturing gene therapies to expand

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Emergency workers more likely to restrain Black patients: study

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Smaller biotechs seek to piggyback on weight loss drug boom

leisure time

focus

leisure time

explore